Vector design influences hepatic genotoxicity after adeno-associated virus gene therapy
Open accessThe DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Abstract
The use of adeno-associated virus (AAV) as a gene therapy vector has been approved recently for clinical use and has demonstrated efficacy in a growing number of clinical trials. However, the safety of AAV as a vector has been challenged by a single study that documented hepatocellular carcinoma (HCC) after AAV gene delivery in mice. Most studies have not noted genotoxicity following AAV-mediated gene delivery; therefore, the possibility that there is an association between AAV and HCC is controversial. Here, we performed a comprehensive study of HCC in a large number of mice following therapeutic AAV gene delivery. Using a sensitive high-throughput integration site-capture technique and global expressional analysis, we found that AAV integration into the RNA imprinted and accumulated in nucleus (Rian) locus, and the resulting overexpression of proximal microRNAs and retrotransposon-like 1 (Rtl1) were associated with HCC. In addition, we demonstrated that the AAV vector dose, enhancer/promoter selection, and the timing of gene delivery are all critical factors for determining HCC incidence after AAV gene delivery. Together, our results define aspects of AAV-mediated gene therapy that influence genotoxicity and suggest that these features should be considered for design of both safer AAV vectors and gene therapy studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“preclinical data suggest AAV integration events occur in a dose-dependent manner with a preference for integration at sites of active transcription, tissue-specific promoters are protective against oncogenesis.178, 179, 180”
From Current clinical applications of in vivo gene therapy with AAVs (2021) · cites this paper as [179]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cutadapt removes adapter sequences from high-throughput sequencing reads
Martin, M. (2011) · EMBnet.journal · doi:10.14806/ej.17.1.200 · Cited by 33,889 · cited 1×
“GCGCGCTCGCTCG-3′) were trimmed by cutadapt (57).”
Ultrafast and memory-efficient alignment of short DNA sequences to the human genome.
Langmead, B., Trapnell, C., Pop, M., & Salzberg, S. L. (2009) · Genome Biology · doi:10.1186/gb-2009-10-3-r25 · Cited by 21,849
The Human Genome Browser at UCSC
Kent, W. J., Sugnet, C. W., Furey, T. S., Roskin, K. M., Pringle, T. H., Zahler, A. M., & Haussler, A. D. (2002) · Genome Research · doi:10.1101/gr.229102 · Cited by 10,400 · cited 2×
“Mouse BLAT (61, 62) (assembly December 2011 Genome Reference Consortium Mouse Build 38/mm10) was used to align the resultant sequence to the murine genome.”
<tt>BLAT</tt> —The <tt>BLAST</tt> -Like Alignment Tool
Kent, W. J. (2002) · Genome Research · doi:10.1101/gr.229202 · Cited by 8,480 · cited 2×
“Mouse BLAT (61, 62) (assembly December 2011 Genome Reference Consortium Mouse Build 38/mm10) was used to align the resultant sequence to the murine genome.”
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163 · cited 1×
“To investigate this possibility, we developed a vector, AAV8-hAAT-synMUT, modeled on a AAV vector that had been administered to human subjects with hemophilia and did not cause genotoxicity in mice (13, 33).”
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145 · cited 1×
“In fact, there are multiple human AAV gene therapy trials around the world that have been completed, are accruing participants, or are in preparation (4), and recent studies using AAV to treat 3 genetic disorders have been regarded as successful (5–8).”
Effect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924
A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency
Hacein-Bey-Abina, S., von Kalle, C., Schmidt, M., Le Deist, F., Wulffraat, N., McIntyre, E., Radford, I., Villeval, J.-L., Fraser, C. C., Cavazzana-Calvo, M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejm200301163480314 · Cited by 1,867 · cited 1×
“The most relevant example is the failure of animal studies to predict the increased risk for the development of leukemia after retroviral gene therapy for X-linked severe combined immunity deficiency (45).”
Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864
Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy
Gao, G.-P., Alvira, M. R., Wang, L., Calcedo, R., Johnston, J., & Wilson, J. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182412299 · Cited by 1,520 · cited 2×
“…the use of a more hepatotrophic serotype, such as AAV8 compared with AAV2, led to an increase in the rate of HCC. Additionally, the use of distinct capsids to pseudotype AAV vectors (48), such as serotypes 8 and 9, confers distinct patterns of tissue troph-ism in wild-type and disease states (49).”
Research works printed but not linked: 1
- Martin, 2011, EMBnetJ., 17
Cited by
Adeno-associated virus vector as a platform for gene therapy delivery
Wang, D., Tai, P. W. L., & Gao, G. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0012-9 · Cited by 2,444
Gene therapy returns to centre stage
Naldini, L. (2015) · Nature · doi:10.1038/nature15818 · Cited by 1,184
Emerging issues in AAV-mediated in vivo gene therapy
Colella, P., Ronzitti, G., & Mingozzi, F. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2017.11.007 · Cited by 881
“This integration leads to the dysregulation of genes (Rlt1 and various microRNAs) flanking the insertion site promoting HCC.(155) Notably, in humans, the Rian locus is not present, although upregulation of delta-like homolog 1-deiodinase type 3 (DLK1-DIO3) locus, the human ortholog of the Rian microRNA locus, has been…”
BackgroundInfluentialHemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant
George, L. A., Sullivan, S. K., Giermasz, A., Rasko, J. E. J., Samelson-Jones, B. J., Ducore, J., Cuker, A., Sullivan, L. M., Majumdar, S., Teitel, J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708538 · Cited by 762
Current clinical applications of in vivo gene therapy with AAVs
Mendell, J. R., Al-Zaidy, S. A., Rodino-Klapac, L. R., Goodspeed, K., Gray, S. J., Kay, C. N., Boye, S. L., Boye, S. E., George, L. A., Salabarria, S., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.12.007 · Cited by 743
High, K. A., & Roncarolo, M. G. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1706910 · Cited by 555
Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas
Nault, J.-C., Datta, S., Imbeaud, S., Franconi, A., Mallet, M., Couchy, G., Letouzé, E., Pilati, C., Verret, B., Blanc, J.-F., et al. (2015) · Nature Genetics · doi:10.1038/ng.3389 · Cited by 489
Umemura, A., He, F., Taniguchi, K., Nakagawa, H., Yamachika, S., Font-Burgada, J., Zhong, Z., Subramaniam, S., Raghunandan, S., Duran, A., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.04.006 · Cited by 463
“Although AAV injection into mice was reported to induce occasional liver tumors, these tumors were found at 14–25 months after infection (Chandler et al., 2015), well beyond the time point at which we examined our mice.”
BackgroundLong-term evaluation of AAV-CRISPR genome editing for Duchenne muscular dystrophy
Nelson, C. E., Wu, Y., Gemberling, M. P., Oliver, M. L., Waller, M. A., Bohning, J. D., Robinson-Hamm, J. N., Bulaklak, K., Castellanos Rivera, R. M., Collier, J. H., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0344-3 · Cited by 430
Nguyen, G. N., Everett, J. K., Kafle, S., Roche, A. M., Raymond, H. E., Leiby, J., Wood, C., Assenmacher, C.-A., Merricks, E. P., Long, C. T., et al. (2021) · Nature Biotechnology · doi:10.1038/s41587-020-0741-7 · Cited by 424
High levels of AAV vector integration into CRISPR-induced DNA breaks
Hanlon, K. S., Kleinstiver, B. P., Garcia, S. P., Zaborowski, M. P., Volak, A., Spirig, S. E., Muller, A., Sousa, A. A., Tsai, S. Q., Bengtsson, N. E., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12449-2 · Cited by 431
Blood-Brain Barrier and Delivery of Protein and Gene Therapeutics to Brain
Pardridge, W. M. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00373 · Cited by 405
“Long term (2 year) studies in mice show a 50%–75% incidence of hepatocellular carcinoma (HCC) in newborn mice treated with a single IV injection dose (ID) of 1014 vg/kg of AAV (Chandler et al., 2015).”
BackgroundTherapeutic AAV Gene Transfer to the Nervous System: A Clinical Reality
Hudry, E., & Vandenberghe, L. H. (2019) · Neuron · doi:10.1016/j.neuron.2019.02.017 · Cited by 369
CRISPR-mediated activation of a promoter or enhancer rescues obesity caused by haploinsufficiency
Matharu, N., Rattanasopha, S., Tamura, S., Maliskova, L., Wang, Y., Bernard, A., Hardin, A., Eckalbar, W. L., Vaisse, C., & Ahituv, N. (2019) · Science · doi:10.1126/science.aau0629 · Cited by 323
Systemic Messenger RNA Therapy as a Treatment for Methylmalonic Acidemia
An, D., Schneller, J. L., Frassetto, A., Liang, S., Zhu, X., Park, J.-S., Theisen, M., Hong, S.-J., Zhou, J., Rajendran, R., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.11.081 · Cited by 263
Self-citationMultiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A
George, L. A., Monahan, P. E., Eyster, M. E., Sullivan, S. K., Ragni, M. V., Croteau, S. E., Rasko, J. E. J., Recht, M., Samelson-Jones, B. J., MacDougall, A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2104205 · Cited by 243
Sabatino, D. E., Bushman, F. D., Chandler, R. J., Crystal, R. G., Davidson, B. L., Dolmetsch, R., Eggan, K. C., Gao, G., Gil-Farina, I., Kay, M. A., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.06.004 · Cited by 212
“To date, the genotoxicity associated with rAAV integrations in the Rian locus is derived from studies that treated mice as neonates at day 1 or 2 postpartum.(42,46,56,57,60) Increased rates of tumorigenesis, after treatment rAAV of juvenile/adult has been reported in WT mice treated with a LacZ vector but it is unclea…”
BackgroundMethodInfluentialSelf-citationCheng, Q., Wei, T., Jia, Y., Farbiak, L., Zhou, K., Zhang, S., Wei, Y., Zhu, H., & Siegwart, D. J. (2018) · Advanced Materials · doi:10.1002/adma.201805308 · Cited by 221
A Historical Review of Brain Drug Delivery
Pardridge, W. M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061283 · Cited by 219
Gene Therapy for Duchenne Muscular Dystrophy
Elangkovan, N., & Dickson, G. (2021) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-210678 · Cited by 196
“Concerns regarding genotoxicity have emerged as in certain circumstances there seems to be a dosedependent correlation between AAV gene delivery and hepatocellular carcinoma (HCC), indicating that increasing the AAV dosage could increase genotoxicity [90].”
BackgroundGeorge, L. A., Ragni, M. V., Rasko, J. E. J., Raffini, L. J., Samelson-Jones, B. J., Ozelo, M., Hazbon, M., Runowski, A. R., Wellman, J. A., Wachtel, K., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.06.001 · Cited by 213
“It remains unclear but possible that use of higher vector doses and steroids to maintain transduced hepatocytes may carry greater long-term vector-related safety concerns; indeed, this would be consistent with data previously published in mouse models.(13) Alternatively, use of higher vector doses may reflect less eff…”
BackgroundResultInfluentialRecombinant Adeno-Associated Viral Integration and Genotoxicity: Insights from Animal Models
Chandler, R. J., Sands, M. S., & Venditti, C. P. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.009 · Cited by 203
“Genes that are frequent targets of rAAV integration from Chandler et al.(50)”
InfluentialSelf-citationDurable and efficient gene silencing in vivo by hit-and-run epigenome editing
Cappelluti, M. A., Mollica Poeta, V., Valsoni, S., Quarato, P., Merlin, S., Merelli, I., & Lombardo, A. (2024) · Nature · doi:10.1038/s41586-024-07087-8 · Cited by 188
“This approach poses safety concerns for clinical translation, as inserting vectors into the host genome can lead to mutagenesis 17,18 whereas prolonged expression of editors could promote their off-targeting activity, as previously shown 19 for CRISPR–Cas9.”
BackgroundUpdate on clinical gene therapy for hemophilia
Perrin, G. Q., Herzog, R. W., & Markusic, D. M. (2019) · Blood · doi:10.1182/blood-2018-07-820720 · Cited by 175
Gil-Farina, I., Fronza, R., Kaeppel, C., Lopez-Franco, E., Ferreira, V., D'Avola, D., Benito, A., Prieto, J., Petry, H., Gonzalez-Aseguinolaza, G., et al. (2016) · Molecular Therapy · doi:10.1038/mt.2016.52 · Cited by 179
In vivo topical gene therapy for recessive dystrophic epidermolysis bullosa: a phase 1 and 2 trial
Gurevich, I., Agarwal, P., Zhang, P., Dolorito, J. A., Oliver, S., Liu, H., Reitze, N., Sarma, N., Bagci, I. S., Sridhar, K., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01737-y · Cited by 169
Viral Vectors: The Road to Reducing Genotoxicity
David, R. M., & Doherty, A. T. (2017) · Toxicological Sciences · doi:10.1093/toxsci/kfw220 · Cited by 170
rAAV immunogenicity, toxicity, and durability in 255 clinical trials: A meta-analysis
Shen, W., Liu, S., & Ou, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1001263 · Cited by 173
“In addition, the risk also depends on promoter choice as shown in a murine study (86).”
BackgroundGreig, J. A., Martins, K. M., Breton, C., Lamontagne, R. J., Zhu, Y., He, Z., White, J., Zhu, J.-X., Chichester, J. A., Zheng, Q., et al. (2024) · Nature Biotechnology · doi:10.1038/s41587-023-01974-7 · Cited by 145
Addressing high dose AAV toxicity – ‘one and done’ or ‘slower and lower’
Kishimoto, T. K., & Samulski, R. J. (2022) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2060737 · Cited by 152
“HCC has been primarily associated with vector integration at high AAV doses in neonatal mice, particularly with vectors that employ a strong promoter that may result in transactivation of protooncogenes [15,16].”
BackgroundTruong, B., Allegri, G., Liu, X.-B., Burke, K. E., Zhu, X., Cederbaum, S. D., Häberle, J., Martini, P. G. V., & Lipshutz, G. S. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1906182116 · Cited by 151
“These include risk for insertional mutagenesis (24) and limited efficacy due to hepatocellular division (25) with viral-based strategies, lack of availability of cellular-based strategies (42) and organ-based strategies (43), and inability for hepatocyte penetrance with PEGylated enzyme replacement (11).”
BackgroundNext-generation AAV vectors—Do not judge a virus (only) by its cover
Domenger, C., & Grimm, D. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddz148 · Cited by 147
Gene therapy: progress and predictions
Collins, M. K., & Thrasher, A. J. (2015) · Proceedings of the Royal Society B Biological Sciences · doi:10.1098/rspb.2014.3003 · Cited by 178
Phase I open label liver-directed gene therapy clinical trial for acute intermittent porphyria
D’Avola, D., López-Franco, E., Sangro, B., Pañeda, A., Grossios, N., Gil-Farina, I., Benito, A., Twisk, J., Paz, M., Ruiz, J., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.05.012 · Cited by 143
Adeno-Associated Virus Gene Therapy for Liver Disease
Kattenhorn, L. M., Tipper, C. H., Stoica, L., Geraghty, D. S., Wright, T. L., Clark, K. R., & Wadsworth, S. C. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.160 · Cited by 138
“further examines the role of AAV integration in the formation of HCC in mice.(116) Similar to previous studies, it was demonstrated that AAV most frequently integrates into highly expressed genes, including albumin and a-fetoprotein.”
ResultAdeno-Associated Virus Gene Therapy for Hemophilia
Samelson‐Jones, B. J., & George, L. A. (2022) · Annual Review of Medicine · doi:10.1146/annurev-med-043021-033013 · Cited by 150
The promise of microRNA-based therapies in Alzheimer’s disease: challenges and perspectives
Walgrave, H., Zhou, L., De Strooper, B., & Salta, E. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00496-7 · Cited by 131
A Self-Deleting AAV-CRISPR System for In Vivo Genome Editing
Li, A., Lee, C. M., Hurley, A. E., Jarrett, K. E., De Giorgi, M., Lu, W., Balderrama, K. S., Doerfler, A. M., Deshmukh, H., Ray, A., et al. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.11.009 · Cited by 128
“It is well known that treatment of neonatal mice with high doses of recombinant AAV vectors can result in tumor formation in the liver through integration into the Rian locus, via cis-acting effects of strong promoter elements.(36) Likewise, a recent report identified wild-type AAV2 integrations in known tumor suppres…”
BackgroundAdeno-associated virus in the liver: natural history and consequences in tumour development
La Bella, T., Imbeaud, S., Peneau, C., Mami, I., Datta, S., Bayard, Q., Caruso, S., Hirsch, T. Z., Calderaro, J., Morcrette, G., et al. (2020) · Gut · doi:10.1136/gutjnl-2019-318281 · Cited by 128
AAV integration in human hepatocytes
Dalwadi, D. A., Calabria, A., Tiyaboonchai, A., Posey, J., Naugler, W. E., Montini, E., & Grompe, M. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.08.031 · Cited by 126
Meliani, A., Boisgerault, F., Fitzpatrick, Z., Marmier, S., Leborgne, C., Collaud, F., Simon Sola, M., Charles, S., Ronzitti, G., Vignaud, A., et al. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017010181 · Cited by 127
Methylmalonic acidemia: Current status and research priorities
Zhou, X., Cui, Y., & Han, J. (2018) · Intractable & Rare Diseases Research · doi:10.5582/irdr.2018.01026 · Cited by 125
“Although genotoxicity was observed in the mouse studies with some vectors, it has been demonstrated that manipulating regulatory elements and AAV dosing could reduce the genotoxicity (21).”
BackgroundAdvances and innovations in haemophilia treatment
Peters, R., & Harris, T. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.70 · Cited by 122
Jin, Y., Lee, J. S., Kim, J., Min, S., Wi, S., Yu, J. H., Chang, G.-E., Cho, A.-N., Choi, Y., Ahn, D.-H., et al. (2018) · Nature Biomedical Engineering · doi:10.1038/s41551-018-0260-8 · Cited by 111
Principles of Genetic Engineering
Lanigan, T. M., Kopera, H. C., & Saunders, T. L. (2020) · Genes · doi:10.3390/genes11030291 · Cited by 133
Baruteau, J., Waddington, S. N., Alexander, I. E., & Gissen, P. (2017) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-017-0053-3 · Cited by 110
“Integration occurred in the Rian hotspot, a rodent-specific locus absent in other vertebrate genomes (Chandler et al 2015).”
BackgroundRubin, J., Nguyen, T. V., Allen, K. L., Ayasoufi, K., & Barry, M. (2019) · Human Gene Therapy · doi:10.1089/hum.2019.127 · Cited by 93
Liver Injury Increases the Incidence of HCC following AAV Gene Therapy in Mice
Dalwadi, D. A., Torrens, L., Abril-Fornaguera, J., Pinyol, R., Willoughby, C., Posey, J., Llovet, J. M., Lanciault, C., Russell, D. W., Grompe, M., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.10.018 · Cited by 105
“The majority of experimental evidence to date suggests that rAAV gene therapy is safe, but there are some compelling rodent studies that provide evidence of potential genotoxicity of rAAV vectors.(5) For example, when neonatal mice were infected with a rAAV gene therapy vector, the mice that received the vector were f…”
BackgroundShort DNA Hairpins Compromise Recombinant Adeno-Associated Virus Genome Homogeneity
Xie, J., Mao, Q., Tai, P. W. L., He, R., Ai, J., Su, Q., Zhu, Y., Ma, H., Li, J., Gong, S., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.03.028 · Cited by 102
Gene therapy for hemophilia: what does the future hold?
Doshi, B. S., & Arruda, V. R. (2018) · Therapeutic Advances in Hematology · doi:10.1177/2040620718791933 · Cited by 97
Mashel, T. V., Tarakanchikova, Y. V., Muslimov, A. R., Zyuzin, M. V., Timin, A. S., Lepik, K. V., & Fehse, B. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120282 · Cited by 105
All‐In‐One Dendrimer‐Based Lipid Nanoparticles Enable Precise HDR‐Mediated Gene Editing In Vivo
Farbiak, L., Cheng, Q., Wei, T., Álvarez‐Benedicto, E., Johnson, L. T., Lee, S. M., & Siegwart, D. J. (2021) · Advanced Materials · doi:10.1002/adma.202006619 · Cited by 108
Somatic genome editing with CRISPR/Cas9 generates and corrects a metabolic disease
Jarrett, K. E., Lee, C. M., Yeh, Y.-H., Hsu, R. H., Gupta, R., Zhang, M., Rodriguez, P. J., Lee, C. S., Gillard, B. K., Bissig, K.-D., et al. (2017) · Scientific Reports · doi:10.1038/srep44624 · Cited by 97
AAV vector development, back to the future
Suárez-Amarán, L., Song, L., Tretiakova, A. P., Mikhail, S., & Samulski, R. J. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.064 · Cited by 104
Uchida, S., & Kataoka, K. (2019) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.36614 · Cited by 88
Treatment of Hemophilia A Using Factor VIII Messenger RNA Lipid Nanoparticles
Chen, C.-Y., Tran, D. M., Cavedon, A., Cai, X., Rajendran, R., Lyle, M. J., Martini, P. G. V., & Miao, C. H. (2020) · Molecular Therapy Nucleic Acids · doi:10.1016/j.omtn.2020.03.015 · Cited by 89
FGF21 underlies a hormetic response to metabolic stress in methylmalonic acidemia
Manoli, I., Sysol, J. R., Epping, M. W., Li, L., Wang, C., Sloan, J. L., Pass, A. R., Gagné, J., Ktena, Y. P., Li, L., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.124351 · Cited by 88
“Next, a canonical adeno-associated virus (AAV) gene therapy vector configured to express human MUT cDNA under the control of the ApoE-enhanced, human α 1 antitrypsin promoter/enhancer combination (AAV2/8 hAAT MUT) was packaged with a serotype 8 capsid (38) and systemically delivered via a retro-orbital injection at a…”
MethodSelf-citationMonahan, P. E., Négrier, C., Tarantino, M., Valentino, L. A., & Mingozzi, F. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10112471 · Cited by 85
ZFN-mediated in vivo genome editing corrects murine hurler syndrome
Ou, L., DeKelver, R. C., Rohde, M., Tom, S., Radeke, R., St. Martin, S. J., Santiago, Y., Sproul, S., Przybilla, M. J., Koniar, B. L., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2018.10.018 · Cited by 84
“Additionally, we observed no incidences of hepatocellular carcinoma (HCC), which has been previously associated with AAV-based gene therapy in mice.(21) In the referenced study, neonatal mice were treated with AAV vectors, and HCC was associated with insertion at a locus not conserved in humans.”
ResultCell and gene therapy for kidney disease
Peek, J. L., & Wilson, M. H. (2023) · Nature Reviews Nephrology · doi:10.1038/s41581-023-00702-3 · Cited by 94
Reichel, F. F., Michalakis, S., Wilhelm, B., Zobor, D., Muehlfriedel, R., Kohl, S., Weisschuh, N., Sothilingam, V., Kuehlewein, L., Kahle, N., et al. (2022) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2021-319067 · Cited by 72
Modulating gene regulation to treat genetic disorders
Matharu, N. K., & Ahituv, N. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0083-7 · Cited by 85
Colella, P., Sellier, P., Costa Verdera, H., Puzzo, F., van Wittenberghe, L., Guerchet, N., Daniele, N., Gjata, B., Marmier, S., Charles, S., et al. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.11.002 · Cited by 74
“In the tandem promoters, the ApoE-hAAT sequences were positioned upstream of the additional promoter elements based on the reported low transactivation activity in case of AAV integration in the genomic DNA.(58) As controls for the specificity and the potency of the tandem promoters, we generated expression cassettes…”
MethodInfluentialAdeno-associated viral vectors for the treatment of hemophilia
High, K. A., & Anguela, X. M. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddv475 · Cited by 73
“Inmice, the incidence of HCC is highly dependent on the AAV vector dose, the ability of the regulatory elements to promote increased transcription of proximal genes and the timing of vector delivery (neonatal versus adult administration) (41).”
BackgroundGene therapy for Mucopolysaccharidoses
Sawamoto, K., Chen, H.-H., Alméciga-Díaz, C. J., Mason, R. W., & Tomatsu, S. (2017) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2017.12.434 · Cited by 88
“The AAV vector dose, its constructs selection including promoter/enhancer, and the timing of administration can be all critical factors that could lead to hepatocellular carcinoma [37,109].”
Advances in the management of haemophilia: emerging treatments and their mechanisms
Okaygoun, D., Oliveira, D. D., Soman, S., & Williams, R. (2021) · Journal of Biomedical Science · doi:10.1186/s12929-021-00760-4 · Cited by 86
Gene therapy for liver diseases — progress and challenges
Zabaleta, N., Unzu, C., Weber, N. D., & González‐Aseguinolaza, G. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00729-0 · Cited by 82
Adeno-Associated Virus Type 2 and Hepatocellular Carcinoma?
Berns, K. I., Byrne, B. J., Flotte, T. R., Gao, G., Hauswirth, W. W., Herzog, R. W., Muzyczka, N., VandenDriessche, T., Xiao, X., Zolotukhin, S., et al. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.29014.kib · Cited by 76
Curative ex vivo liver-directed gene therapy in a pig model of hereditary tyrosinemia type 1
Hickey, R. D., Mao, S. A., Glorioso, J., Elgilani, F., Amiot, B., Chen, H., Rinaldo, P., Marler, R., Jiang, H., DeGrado, T. R., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf3838 · Cited by 75
“However, despite the clear demonstration of safety to date of LV in the clinic for primary immunodeficiencies, further work to test genotoxicity of LV in human hepatocytes is required before initiation of any clinical trials, particularly given the recent data on genotoxicity of other viral vectors, including AAV, in…”
BackgroundValdmanis, P. N., Kim, H. K., Chu, K., Zhang, F., Xu, J., Munding, E. M., Shen, J., & Kay, M. A. (2018) · Nature Communications · doi:10.1038/s41467-018-07786-7 · Cited by 72
Curing hemophilia A by NHEJ-mediated ectopic F8 insertion in the mouse
Zhang, J.-P., Cheng, X.-X., Zhao, M., Li, G.-H., Xu, J., Zhang, F., Yin, M.-D., Meng, F.-Y., Dai, X.-Y., Fu, Y.-W., et al. (2019) · Genome Biology · doi:10.1186/s13059-019-1907-9 · Cited by 71
“One study showed that genes known to have higher expression in the liver, such as albumin, are hotspots for AAV integration [39].”
BackgroundMücke, M. M., Fong, S., Foster, G. R., Lillicrap, D., Miesbach, W., & Zeuzem, S. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.10.029 · Cited by 81
In Vivo Delivery of Nucleic Acid-Encoded Monoclonal Antibodies
Patel, A. R., Bah, M. A., & Weiner, D. B. (2020) · BioDrugs · doi:10.1007/s40259-020-00412-3 · Cited by 78
Jiang, D., Lee, H., & Pardridge, W. M. (2020) · Scientific Reports · doi:10.1038/s41598-020-70290-w · Cited by 75
Adeno-associated Vector Toxicity—To Be or Not to Be?
Büning, H., & Schmidt, M. (2015) · Molecular Therapy · doi:10.1038/mt.2015.182 · Cited by 71
Bosch, M. E., Aldrich, A., Fallet, R., Odvody, J., Burkovetskaya, M., Schuberth, K., Fitzgerald, J. A., Foust, K. D., & Kielian, T. (2016) · The Journal of Neuroscience · doi:10.1523/jneurosci.1635-16.2016 · Cited by 69
“, 2016); however, this is typically observed when virus is administered to neonatal mice (Donsante et al., 2007; Chandler et al., 2015), which differs from our study, in which scAAV9 was used in juvenile animals.”
ResultBaek, R. C., Coughlan, K. A., Jiang, L., Liang, M., Ci, L., Singh, H., Zhang, H., Kaushal, N., Rajlic, I. L., Van, L. M., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47460-9 · Cited by 80
Genotoxicity in Mice Following AAV Gene Delivery: A Safety Concern for Human Gene Therapy?
Chandler, R. J., LaFave, M. C., Varshney, G. K., Burgess, S. M., & Venditti, C. P. (2016) · Molecular Therapy · doi:10.1038/mt.2016.17 · Cited by 70
Self-citationGene Therapy for Lysosomal Storage Disorders: Ongoing Studies and Clinical Development
Massaro, G., Geard, A. F., Liu, W., Coombe-Tennant, O., Waddington, S. N., Baruteau, J., Gissen, P., & Rahim, A. A. (2021) · Biomolecules · doi:10.3390/biom11040611 · Cited by 68
Regulation of hepatocyte identity and quiescence
Berasain, C., & Avila, M. A. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-1970-7 · Cited by 68
“Nevertheless, administration of AAV vectors to patients with chronic liver disease is not exempt from risks [208], and also strategies to avoid the immune response to AAVs found in humans need to be optimized [209].”
BackgroundAAV Engineering for Improving Tropism to the Central Nervous System
Ghauri, M. S., & Ou, L. (2023) · Biology · doi:10.3390/biology12020186 · Cited by 74
Porro, F., Bortolussi, G., Barzel, A., Caneva, A. D., Iaconcig, A., Vodret, S., Zentilin, L., Kay, M. A., & Muro, A. F. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201707601 · Cited by 65
“On the other hand, the proposed strategy should limit some concerns present with other gene therapy approaches (Valdmanis et al , 2012; Fu et al , 2013), such as increased risk of developing HCC by off-target insertion of promoter-driven constructs (Donsante et al , 2007; Chandler et al , 2015).”
Delivery Approaches for Therapeutic Genome Editing and Challenges
Ates, I., Rathbone, T., Stuart, C., Bridges, P. H., & Cottle, R. N. (2020) · Genes · doi:10.3390/genes11101113 · Cited by 63
“The findings led to controversy: separate studies reported no AAV integration events [127].”
BackgroundResultHemophilia gene therapy comes of age
George, L. A. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017009878 · Cited by 62
“This work supported using the lowest possible vector dose, targeting postmitotic hepatocytes, and using a liver-restricted promoter, such as human a-1-antitrypsin, to minimize the theoretical risk of insertional mutagenesis previously identified in preclinical studies.(28)”
MethodAdvances in gene therapy for hemophilia: basis, current status, and future perspectives
Ohmori, T. (2018) · International Journal of Hematology · doi:10.1007/s12185-018-2513-4 · Cited by 93
Breton, C., Clark, P. M., Wang, L., Greig, J. A., & Wilson, J. M. (2020) · BMC Genomics · doi:10.1186/s12864-020-6655-4 · Cited by 57
Hemophilia gene therapy comes of age
George, L. A. (2017) · Hematology · doi:10.1182/asheducation-2017.1.587 · Cited by 58
“This work supported using the lowest possible vector dose, targeting postmitotic hepatocytes, and using a liver-restricted promoter, such as human a-1-antitrypsin, to minimize the theoretical risk of insertional mutagenesis previously identified in preclinical studies.(28)”
MethodSchmidt, M., Foster, G. R., Coppens, M., Thomsen, H., Dolmetsch, R. E., Heijink, L., Monahan, P. E., & Pipe, S. W. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023009876 · Cited by 64
“Nevertheless, the microRNA-341 locus found to be susceptible to rAAV insertional mutagenesis in mice has no human homolog.(5)”
BackgroundGenome editing for inborn errors of metabolism: advancing towards the clinic
Schneller, J. L., Lee, C. M., Bao, G., & Venditti, C. P. (2017) · BMC Medicine · doi:10.1186/s12916-017-0798-4 · Cited by 64
“tion into the genome do occur and can exhibit genotoxic effects [13, 14] dependent upon vector configuration and”
BackgroundSelf-citationChandler, R. J., Venturoni, L. E., Liao, J., Hubbard, B. T., Schneller, J. L., Hoffmann, V. J., Gordo, S., Zang, S., Ko, C., Chau, N., et al. (2020) · Hepatology · doi:10.1002/hep.31570 · Cited by 61
Self-citationOu, L., Przybilla, M. J., Ahlat, O., Kim, S., Overn, P., Jarnes, J., O’Sullivan, M. G., & Whitley, C. B. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.03.018 · Cited by 56
“Previous studies have shown that AAV gene therapy could cause AAV vector integration and thus hepatocellular carcinoma.(33,49,50) In this study, the mouse with the tumor was found dead in the cage during a weekend, and it was not certain how long it had been dead.”
BackgroundIlyinskii, P. O., Michaud, A. M., Roy, C. J., Rizzo, G. L., Elkins, S. L., Capela, T., Chowdhury, A. C., Leung, S. S., & Kishimoto, T. K. (2021) · Science Advances · doi:10.1126/sciadv.abd0321 · Cited by 56
Mattar, C. N. Z., Gil-Fariña, I., Rosales, C., Johana, N. B., Tan, Y., McIntosh, J., Kaeppel, C., Waddington, S. N., Biswas, A., Choolani, M. A., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.04.003 · Cited by 55
Torres‐Torronteras, J., Cabrera-Pérez, R., Vila‐Julià, F., Viscomi, C. F., Cámara, Y., Hirano, M., Zeviani, M., & Martí, R. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.133 · Cited by 56
“Of note, this study treated adult mice and not newborns, and the doses administered were 50 times lower than those resulting in tumorigenesis.(49) Thus, at the doses used, it seems that the genotoxic potential of the vector is low, but the therapeutic benefit is retained.”
InfluentialRecent advances in gene therapy for lysosomal storage disorders
Amalfitano, A., & Rastall, D. P. W. (2015) · The Application of Clinical Genetics · doi:10.2147/tacg.s57682 · Cited by 62
Gene Therapy for Methylmalonic Acidemia: Past, Present, and Future
Chandler, R. J., & Venditti, C. P. (2019) · Human Gene Therapy · doi:10.1089/hum.2019.113 · Cited by 59
Self-citationLi, Y., Miller, C. A., Shea, L. K., Jiang, X., Guzmán, M. A., Chandler, R. J., Ramakrishnan, S. M., Smith, S. N., Venditti, C. P., Vogler, C. A., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.12.031 · Cited by 55
Self-citationDiscussing investigational AAV gene therapy with hemophilia patients: A guide
Sidonio, R. F., Pipe, S. W., Callaghan, M. U., Valentino, L. A., Monahan, P. E., & Croteau, S. E. (2020) · Blood Reviews · doi:10.1016/j.blre.2020.100759 · Cited by 54
Burdett, T., & Nuseibeh, S. (2022) · Gene Therapy · doi:10.1038/s41434-022-00363-0 · Cited by 61
Controlled release strategies for rAAV-mediated gene delivery
Rey‐Rico, A., & Cucchiarini, M. (2015) · Acta Biomaterialia · doi:10.1016/j.actbio.2015.10.015 · Cited by 53
Metadata
- Authors
- Chandler, R. J., LaFave, M. C., Varshney, G. K., Trivedi, N. S., Carrillo-Carrasco, N., Senac, J. S., Wu, W., Hoffmann, V., Elkahloun, A. G., Burgess, S. M., & Venditti, C. P.
- Affiliations
- National Institutes of Health (US)
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2015-01-20
- Volume
- 125
- Issue
- 2
- Pages
- 870-880
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC4319425
- OpenAlex
- W2133112334
- Cited by
- 403
- References
- 63
- Citations by year
- 2026: 28 · 2025: 42 · 2024: 40 · 2023: 38 · 2022: 36 · 2021: 32 · 2020: 45 · 2019: 30 · 2018: 26 · 2017: 32 · 2016: 31 · 2015: 22
- FWCI
- 25.28
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Human Genome Research Institute
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Keywords
- adeno-associated virus, gene therapy vectors, hepatocellular carcinoma, genotoxicity, AAV integration, microRNA overexpression, RTL1, vector dose
- MeSH terms
- Dependovirus, Animals, Genetic Vectors, Carcinoma, Hepatocellular, Liver Neoplasms, Mice, Mutant Strains, Pregnancy Proteins, Transduction, Genetic, Genetic Therapy, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.